Firefighters Who Were Exposed to World Trade Center Debris Found to Have an Increased Risk for a Precancerous Condition

Researchers at Memorial Sloan Kettering (MSK) report that firefighters at the World Trade Center (WTC) scene in September 2001 were nearly twice as likely as the general population to have a multiple myeloma precursor condition called monoclonal...
2-May-2018 12:05 PM EDT Add to Favorites

Pivotal Results from Phase III Trial Show That the Combination of Ipilimumab and Nivolumab Increases Overall Survival in People with Kidney Cancer

Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo®) and ipilimumab (Yervoy®) significantly increased overall survival versus treatment with sunitinib (Sutent®) alone, according...
21-Mar-2018 11:00 AM EDT Add to Favorites

Updated Data Confirms a Durable 75 Percent Overall Response Rate, by Blinded Independent Review, of Larotrectinib in Adults and Children with Tumors Harboring TRK Fusions

Larotrectinib, a highly selective TRK kinase inhibitor, shows rapid, potent, and durable efficacy in both adult and pediatric patients with solid tumors that harbor TRK fusions, regardless of tumor type or patient age, according to results from...
22-Feb-2018 10:05 AM EST Add to Favorites

Increased Breast Cancer Risk Seen in Postmenopausal Women with High Body-Fat Levels Despite Normal BMI

The risk of invasive breast cancer is increased in postmenopausal women with a normal body mass index (BMI) but higher levels of body fat, meaning that a large portion of the population has an unrecognized risk of developing cancer.
9-Feb-2018 12:05 PM EST Add to Favorites

Viviane Tabar, MD, Named Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center

Viviane Tabar, MD, has been named the new Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center (MSK). Dr. Tabar has been a vital faculty member at MSK for more than 15 years and is currently the Theresa C. Feng Chair for...
5-Dec-2017 3:45 PM EST Add to Favorites

MSK-IMPACT™ Is the First Tumor-Profiling Multiplex Panel Authorized by the FDA, Setting a New Pathway to Market for Future Oncopanels

The US Food and Drug Administration (FDA) announced today the authorization of MSK-IMPACT™ (which stands for integrated mutation profiling of actionable cancer targets), a high throughput, targeted-DNA-sequencing panel for somatic mutations....
15-Nov-2017 1:00 PM EST Add to Favorites

Young Investigators Named Winners of 2017 Paul Marks Prize for Cancer Research

Memorial Sloan Kettering (MSK) has named three investigators as recipients of this year’s Paul Marks Prize for Cancer Research. The award recognizes promising investigators aged 45 or younger at the time of nomination for their efforts in...
9-Nov-2017 9:05 AM EST Add to Favorites

New Study Findings Unlock the Secret of Why Some People with Pancreatic Cancer Live Longer than Others

The pancreatic cancer and immunotherapy experts at Memorial Sloan Kettering Cancer Center (MSK) have shown for the first time why some people with pancreatic cancer live many more years than others with the deadly disease.
7-Nov-2017 1:05 PM EST Add to Favorites

see all news